 Home > Active Ingredient News >

Blood System

The first in the country! In 2020, TMB testing and clinical application expert consensus came out

 Time of Update: 2020-11-30

1 2 ethanediol 1 heptanol 2 3 dimethylbutane 2 hydroxyglutarate 2 hydroxyacetophenone

testing laboratories should establish appropriate DNA sample quality control standards and operating procedures according to actual needs, and strictly quality control of DNA sample purity, concentration and fragmentation. tumor primary
Is Li Ka-shing's superstitious "life-long medicine" a medical miracle or a cut?

 Time of Update: 2020-11-30

1 2 ethanediol 1 heptanol 2 3 dimethylbutane 2 hydroxyglutarate 2 hydroxyacetophenone

li Ka-shing, his health care products cost 1.5 million yuan a year to take, and if clinical trials are to be conducted, who will pay for them?
Abel Vinaykla film is about to be approved domestic sales are expected to break 1 billion this year...

 Time of Update: 2020-11-30

1 2 ethanediol 1 methoxybutane 2 3 dimethylbutane 2 hydroxyglutarate 2 hydroxyacetophenone

Recently, AbbVie BCL-2 inhibitor "Venecla tablet" market application (JXHS2000002/3/4) entered the administrative approval stage, which means that the drug will soon be approved in China, approved adaptation Symptoms are: combined aza cytosine
Hospitals across the country are cutting prices! The third batch was collected and landed

 Time of Update: 2020-11-29

1 4 cyclohexadiene 16s rrna 4 hydroxyacetophenone 7 methylguanosine abilify drug

, according to Hu Jinglin, one of the key work in 2020, in addition to the implementation of the results of collection, but also to carry out the national organization of high-value medical supplies centralized procurement.
Inventory: A selection of Lancet studies on November 21, 2020

 Time of Update: 2020-11-26

1 3 dioxolane 16s rrna 2d6 inhibitors 3a4 inhibitors 9 fluorenol

) and 5 individual trial papers, for a total of 244,090 patients, of whom 21,492 (8.8%) were over 75 years of age, of whom 11,750 (8.8%) 54.7 per cent received statins, 6209 (28.9 per cent) received ecstasy and 3,533 (16.4 per cent) received PCSK9
Clin Cancer Res: Multiple myeloma . . The "high dose" of amine is not loved

 Time of Update: 2020-11-26

293t cells 4 dimethylaminobenzaldehyde 5 hiaa abilify medication acetal group

This is a multi-center, randomized, open-label clinical trial in which patients with multiple myeloma after ASCT and high doses of lenamin (25 mg/day) consolidation therapy (CT) were randomly assigned to the LenMT 25 mg/day group or 5 mg/day group.
Fda suspends clinical trials of CAR-T therapy UCTCS1 for multiple myeloma

 Time of Update: 2020-11-26

293t cells abilify medication achondroplasia treatment adcc trials adme studies

Pharmaceutical company Cellectis announced today that the FDA has suspended melani-01 Phase I clinical trials designed to assess the effectiveness and safety of CAR-T therapy UCTCS1 in the treatment of recurring multiple myeloma (MM).
Blood: Post-HCT CD4-T cell reconstruction predicts survival prognostics in patients with acute GvHD

 Time of Update: 2020-11-26

293t cells 5 hiaa abilify indications acetylcysteine iv adcc trials

the non-recurrence mortality and overall survival rate of patients with CD4-IR iii-IV aGvHD were included in 591 patients (UMC/PMC 276 and MSK 315) within 100 days of HCT.
Blood: Do high-risk Philadelphia chromosomal-negative ALL adult patients need alllo-HSCT?

 Time of Update: 2020-11-26

2 2 dimethylbutane 2 bromopropane 2 methyltetrahydrofuran 2 oxoglutarate 4 dimethylaminobenzaldehyde

the ALL-HR-11 trial was to assess the outcome of chemotherapy or allo-HSCT in adult ALL patients with HR Ph-neg adults based on mrD levels after end-of-treatment induction and consolidation.
Blood: Recombinant FVIII drug Rurioctocog alfa pegol preventive treatment of haemophilia type A

 Time of Update: 2020-11-26

1 3 dioxolane 2 3 dimethylbutane 2 bromopropane 2 methyltetrahydrofuran 2d6 inhibitors

not prevent bleeding events in all PwHA patients, and the minimum FVIII level according to Pharmacodynamics (PK) should be kept above 10%. PROPEL was a randomized Phase 3 trial that compared the safety and effectiveness of the two FVIII minimum levels
The Lancet: Nuclear export inhibitor XPOVIO significantly prolongs the progression-free survival of patients with relapsed or refrectable multiple myeloma

 Time of Update: 2020-11-25

1 2 ethanediol 16s rrna 2 bromopropane 2 pentanol 3 hexene

most common emergency adverse events (AEs) for blood cell reduction and gastrointestinal symptoms, consistent with previous results reported in other selinexor studies.
The world's first nanoantibody, Caplacizumab, has again been approved by NICE to treat clotting disorders in patients with rare diseases, following the FDA and EMA

 Time of Update: 2020-11-25

4 dimethylaminobenzaldehyde aaps 2019 abilify interactions acquired angioedema adderall interactions

The Uk's National Institute for Health and Clinical Excellence (NICE) has approved Sanofi's Caplacizumab for the treatment of acquired thrombosis plateboard reduced cyanosis (aTTP), a rare and potentially life-threatening blood clotting disorder.
Blood: Risk of recurrence after all-all child patients were deactivation of winteramidease

 Time of Update: 2020-11-25

1 propanamine 5 methylcytosine 7 methylguanosine abilify drug achondroplasia treatment

The important role of tiandonamidease in the treatment of acute lymphoblastic leukemia (ALL) has been clarified. Based on most current treatments, the overall survival rate of ALL children has exceeded 90%, but the toxicity associated
Blood: Nano monoantigen Caplacizumab is actually used in real clinical data in TTP patients

 Time of Update: 2020-11-25

16s rrna 3 to 5 exonuclease 5 methylcytosine 7 methylguanosine achondroplasia treatment

The plasma exchange (PEX) joint immunomodulation strategy is the basis for life-saving treatment of immuno-mediated plateplate reduction cyanosis (iTTP). Caplacizumab is a new type of anti-von Willebrand factor nanosome, and the results of two
Blood: Salbonate enhances the anti-tumor activity of CRM1 inhibitors

 Time of Update: 2020-11-25

1 propanamine 2d6 inhibitors 3a4 inhibitors abiraterone mechanism of action acros organics

activity of CRM1 inhibitors by extending the action mechanism beyond the inhibition mechanism to suppress CRM1. Selinexor, when used in a combined way with salbonate, can target a range of blood tumors at lower doses and can also reduce clinical
Blood: Endotopic mesh-related degradation maintains the static and self-renewal of hematopoietic stem cells by limiting mTOR activity

 Time of Update: 2020-11-25

293t cells adderall er akt protein alpha mechanical alzo bank

recently, the latest issue of "ER associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity" reported that the protein quality controlled by endosperm-related degradation (ERAD) regulates the function of resting hematopoietic stem cells (HSCs).
Blood: Activated AKT triggers CLL by overactivated Notch1→ Richter conversion

 Time of Update: 2020-11-25

293t cells acta2 gene adrenogenital syndrome akt protein alstrom syndrome

in mice with E-TCL1 Akt compositional activation induced DLBCL esoteric in the E-TCL1 CLL mouse model, overactivation of the Akt gene led to the conversion of CLL to RT, significantly reducing survival and invasive lymphoma esoteric.
Blood: Characteristics of the evolution and diffusion of multiple myeloma clones

 Time of Update: 2020-11-25

3 stages of cell signaling 5e clone acta2 gene adme studies airclean systems

diffusion model of fluorescent MM cells showed that only a few clones that successfully adapted to the BM micro-environment could enter the bloodstream and be planted in long-range BMs.
ATMP Europe recommended approval of five drugs at its November meeting

 Time of Update: 2020-11-25

134a pressures 2d6 inhibitors 410a pressures abilify drug achondroplasia treatment

CHMP recommends that Phesgo (pertuzumab/trastuzumab) be used to treat early and metastasis HER2-positive breast cancer patients.
JAMA Oncology: Prognostic assessment of the deactivation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

 Time of Update: 2020-11-25

3 to 5 exonuclease 5 methylcytosine aaps 2019 abilify indications achondroplasia treatment

A new study published recently on JAMA Oncology called Assment of Outcomes After Stopping Tyrosine Kinase Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial assessed molecular recurrence (MRec) and prognostics (PROs) reported by patients after CML patients deactivated TKI.

Go to Page

Blood System

The first in the country! In 2020, TMB testing and clinical application expert consensus came out

Is Li Ka-shing's superstitious "life-long medicine" a medical miracle or a cut?

Abel Vinaykla film is about to be approved domestic sales are expected to break 1 billion this year...

Hospitals across the country are cutting prices! The third batch was collected and landed

Inventory: A selection of Lancet studies on November 21, 2020

Clin Cancer Res: Multiple myeloma . . The "high dose" of amine is not loved

Fda suspends clinical trials of CAR-T therapy UCTCS1 for multiple myeloma

Blood: Post-HCT CD4-T cell reconstruction predicts survival prognostics in patients with acute GvHD

Blood: Do high-risk Philadelphia chromosomal-negative ALL adult patients need alllo-HSCT?

Blood: Recombinant FVIII drug Rurioctocog alfa pegol preventive treatment of haemophilia type A

The Lancet: Nuclear export inhibitor XPOVIO significantly prolongs the progression-free survival of patients with relapsed or refrectable multiple myeloma

The world's first nanoantibody, Caplacizumab, has again been approved by NICE to treat clotting disorders in patients with rare diseases, following the FDA and EMA

Blood: Risk of recurrence after all-all child patients were deactivation of winteramidease

Blood: Nano monoantigen Caplacizumab is actually used in real clinical data in TTP patients

Blood: Salbonate enhances the anti-tumor activity of CRM1 inhibitors

Blood: Endotopic mesh-related degradation maintains the static and self-renewal of hematopoietic stem cells by limiting mTOR activity

Blood: Activated AKT triggers CLL by overactivated Notch1→ Richter conversion

Blood: Characteristics of the evolution and diffusion of multiple myeloma clones

ATMP Europe recommended approval of five drugs at its November meeting

JAMA Oncology: Prognostic assessment of the deactivation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia